Elsevier

Pathology

Volume 47, Issue 1, January 2015, Pages 7-12
Pathology

Development and validation of a gene expression tumour classifier for cancer of unknown primary

https://doi.org/10.1097/PAT.0000000000000194Get rights and content

Summary

Accurate identification of the primary tumour in cancer of unknown primary (CUP) is required for effective treatment selection and improved patient outcomes. The aim of this study was to develop and validate a gene expression tumour classifier and integrate it with histopathology to identify the likely site of origin in CUP. RNA was extracted from 450 formalin fixed, paraffin embedded samples of known origin comprising 18 tumour groups. Whole genome expression analysis was performed using a bead-based array. Classification of the tumours made use of a binary support vector machine, together with recursive feature elimination. A hierarchical tumour classifier was developed and incorporated with conventional histopathology to identify the origins of metastatic tumours. The classifier demonstrated an accuracy of 88% for correctly predicting the tumour type on a validation set of known tumours (n = 94). For CUP samples (n = 49) having a final clinical diagnosis, the classifier improved the accuracy of histology alone for both single and multiple predictions. Furthermore, where histology alone could not suggest any specific diagnosis, the classifier was able to correctly predict the primary site of origin. We demonstrate the integration of gene expression profiling with conventional histopathology to aid the investigation of CUP.

References (42)

  • B.J. Schneider et al.

    Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site

    Cancer

    (2007)
  • M.S. Didolkar et al.

    Metastatic carcinomas from occult primary tumors. A study of 254 patients

    Ann Surg

    (1977)
  • T. Le Chevalier et al.

    Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients

    Arch Intern Med

    (1988)
  • J. Mayordomo et al.

    Neoplasms of unknown primary site: a clinicopathological study of autopsied patients

    Tumori

    (1993)
  • J.L. Abbruzzese et al.

    Analysis of a diagnostic strategy for patients with suspected tumors of unknown primary

    J Clin Oncol

    (1995)
  • G.R. Varadhachary et al.

    Diagnostic strategies for unknown primary cancer

    Cancer

    (2004)
  • C. Muir

    Cancers of unknown primary

    Cancer

    (1995)
  • G.G. Anderson et al.

    Determining tissue of origin for metastatic cancers:meta-analysis and literature review of immunohistochemistry performance

    Appl Immunohistochem Mol Morphol

    (2010)
  • J.L. Dennis et al.

    Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm

    Clin Cancer Res

    (2005)
  • A. Bhattacharjee et al.

    Classification of human lung carcinomas by expression profiling reveals distinct adencarcinoma subclasses

    Proc Natl Acad Sci USA

    (2001)
  • B. Weigelt et al.

    Gene expression profiles of primary breast tumours maintained in distinct metastases

    Proc Natl Acad Sci USA

    (2003)
  • Cited by (36)

    • A review on trends in development and translation of omics signatures in cancer

      2024, Computational and Structural Biotechnology Journal
    • Transcriptomics and solid tumors: The next frontier in precision cancer medicine

      2022, Seminars in Cancer Biology
      Citation Excerpt :

      Transcriptomics holds promise as an additional tool for the accurate classification of cancer of unknown primary (CUP). Several investigators have explored gene expression profiles and revealed biomarkers indicative of the origin of the tumor in patients with CUP [52–56,120]. In one study, transcriptome analysis of 16 674 tumors corresponding to 22 tumor types revealed a 154-gene expression signature that aided the identification of tumor origin [120].

    • The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary<sup>✰</sup>: Molecular profiling of metastatic cancer of unknown primary

      2021, Seminars in Diagnostic Pathology
      Citation Excerpt :

      Finally, such a gene expression signature is applied to the identification of tumor type in metastatic CUP (Fig. 1).35-37 The mainstay of gene expression profiling has evolved from real-time reverse transcriptase polymerase chain reaction (RT-PCR)38-46 or microarray-based assays47-56 to whole transcriptome analysis by RNA-sequencing.57-60 A few of these studies utilized fresh frozen tissue from tissue banks.47-49

    • Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?

      2021, Cancer Treatment Reviews
      Citation Excerpt :

      Several retrospective studies have attempted to assess the prediction accuracy of these tests performed on biopsy specimens from patients with CUP. Using correlation with clinicopathological features, the IHC profile or the identification of a latent primary as prediction comparator, these molecular based tissue of origin classifiers yield prediction accuracy from 60% to 92% [15,21–30]. This is corroborated by a prospective study demonstrating an 84% agreement of molecular profile with clinicopathological diagnosis [31].

    View all citing articles on Scopus
    View full text